Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Published October 1, 2018, in The Lancet Neurology (opens in a new window)


Neurological disorders are now the leading source of disability globally, and aging is increasing the burden of neurodegenerative disorders, including Parkinsons disease. We aimed to determine the global burden of Parkinsons disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses.


Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinsons disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinsons disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modeled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinsons disease. Death counts were multiplied by values from the Global Burden of Disease studys standard life expectancy to compute years of life lost. Disability-adjusted life years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility.


In 2016, 6.1 million (95% uncertainty interval [UI] 5.0–7.3) individuals had Parkinsons disease globally, compared with 2.5 million (2.0–3.0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardized prevalence rates increased by 21.7% (95% UI 18.1–25.3) over the same period (compared with an increase of 74.3%, 95% UI 69.2–79.6, for crude prevalence rates). Parkinsons disease caused 3.2 million (95% UI 2.6–4.0) DALYs and 211,296 deaths (95% UI 167,771–265,160) in 2016. The male-to-female ratios of age-standardized prevalence rates were similar in 2016 (1.40, 95% UI 1.36–1.43) and 1990 (1.37, 1.34–1.40). From 1990 to 2016, age-standardized prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, Eastern Europe, and Oceania. In addition, age-standardized DALY rates generally increased across the Socio-demographic Index.


Over the past generation, the global burden of Parkinsons disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinsons disease substantially.

Read full article (opens in a new window)


GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinsons disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology. 1 October 2018. doi:10.1016/S1474-4422(18)30295-3.